Portside Wealth Group LLC Decreases Stock Position in Pfizer Inc. (NYSE:PFE)

Portside Wealth Group LLC lessened its stake in Pfizer Inc. (NYSE:PFE) by 1.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 55,325 shares of the biopharmaceutical company’s stock after selling 1,053 shares during the period. Portside Wealth Group LLC’s holdings in Pfizer were worth $1,601,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Monarch Capital Management Inc. grew its stake in shares of Pfizer by 7.6% during the 4th quarter. Monarch Capital Management Inc. now owns 115,382 shares of the biopharmaceutical company’s stock valued at $3,061,000 after acquiring an additional 8,152 shares during the period. Nexus Investment Management ULC grew its stake in shares of Pfizer by 1.7% during the 4th quarter. Nexus Investment Management ULC now owns 818,287 shares of the biopharmaceutical company’s stock valued at $21,709,000 after acquiring an additional 13,475 shares during the period. Krilogy Financial LLC raised its position in shares of Pfizer by 69.1% during the 4th quarter. Krilogy Financial LLC now owns 46,434 shares of the biopharmaceutical company’s stock valued at $1,232,000 after purchasing an additional 18,975 shares during the period. Ameritas Advisory Services LLC raised its position in shares of Pfizer by 3.6% during the 4th quarter. Ameritas Advisory Services LLC now owns 75,983 shares of the biopharmaceutical company’s stock valued at $2,016,000 after purchasing an additional 2,633 shares during the period. Finally, Integrated Investment Consultants LLC raised its position in shares of Pfizer by 18.1% during the 4th quarter. Integrated Investment Consultants LLC now owns 133,305 shares of the biopharmaceutical company’s stock valued at $3,537,000 after purchasing an additional 20,420 shares during the period. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on PFE. Wolfe Research started coverage on Pfizer in a research note on Friday, November 15th. They set an “underperform” rating and a $25.00 target price on the stock. Sanford C. Bernstein assumed coverage on shares of Pfizer in a research report on Thursday, October 17th. They set a “market perform” rating and a $32.00 target price for the company. UBS Group reduced their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a report on Wednesday, January 8th. Citigroup started coverage on shares of Pfizer in a report on Friday, October 25th. They set a “neutral” rating and a $30.00 price objective for the company. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a report on Wednesday, October 23rd. One analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $32.00.

Pfizer Price Performance

Shares of PFE stock opened at $26.30 on Friday. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The firm has a market capitalization of $149.06 billion, a price-to-earnings ratio of 35.55, a PEG ratio of 0.64 and a beta of 0.64. The stock’s 50-day simple moving average is $26.08 and its 200-day simple moving average is $27.99.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. During the same quarter in the prior year, the business posted ($0.17) EPS. Pfizer’s revenue for the quarter was up 31.2% compared to the same quarter last year. As a group, equities analysts forecast that Pfizer Inc. will post 2.94 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.54%. The ex-dividend date of this dividend is Friday, January 24th. This is an increase from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s payout ratio is presently 232.43%.

Insider Transactions at Pfizer

In other Pfizer news, Director Scott Gottlieb acquired 1,000 shares of the firm’s stock in a transaction on Wednesday, October 30th. The stock was acquired at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the purchase, the director now owns 10,000 shares in the company, valued at approximately $282,400. The trade was a 11.11 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.06% of the company’s stock.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.